Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vimian Group AB ( (SE:VIMIAN) ) has shared an update.
Vimian Group AB has resolved to issue and subsequently repurchase a total of 596,437 additional class D, E1 2025, E2 2025 and E3 2025 shares as part of its previously approved 2025 long-term incentive program based on hurdle shares and employee stock options. The new shares, subscribed by DNB Carnegie Investment Bank at quota value and immediately repurchased by Vimian for later transfer to program participants, slightly increase share capital while using non-dividend, low-vote share classes and deviating from preferential rights specifically to facilitate broader participation and category changes in the incentive plan, aligning employee and management incentives with shareholder interests without materially diluting control or cash flows for existing investors.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a global animal health company operating across Specialty Pharma, MedTech, Veterinary Services and Diagnostics. Headquartered in Stockholm, Sweden, it serves more than 17,000 veterinary clinics and laboratories in over 80 markets, with around 1,200 employees and annual revenues of about EUR 375 million, focusing on innovative products and services for veterinary professionals and pet owners.
YTD Price Performance: -24.92%
Average Trading Volume: 308,681
Technical Sentiment Signal: Sell
Current Market Cap: SEK15.72B
See more insights into VIMIAN stock on TipRanks’ Stock Analysis page.